Consequently, therapeutic strategies that target USP38 or its downstream effectors—such as small-molecule inhibitors or gene-silencing approaches—may provide novel avenues for the precision treatment of CKD-associated AF, with significant translational potential. Here, USP38 is linked to atrial fibrillation.